Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.53 |
| ▸ | ACACA | Q13085 | 3/20 | 0.48 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968246 | 0.90 | ACACA (0.47) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15968050 | 0.90 | MAPT (0.50) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15968555 | 0.88 | ACACA (0.46) | ACACAACACBMAPT | |
| SCHEMBL15968697 | 0.88 | ACACA (0.46) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15968810 | 0.87 | ACACA (0.46) | ESR1ESR2ACACAACACBMTNR1A | |
| SCHEMBL15969007 | 0.86 | ESR1 (0.47) | ESR1ESR2ACACAACACB | |
| SCHEMBL15968748 | 0.86 | ACACA (0.46) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15968897 | 0.86 | ACACB (0.46) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15968470 | 0.85 | ACACB (0.45) | ACACAACACBMTNR1AMTNR1BMAPT | |
| SCHEMBL15969343 | 0.84 | ACACA (0.58) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ESR1 2402/4885ESR2 2876/4885ACACA 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.